The Riverside Company has acquired Global Orthopaedic Technologies, an Australian manufacturer and distributor of orthopaedic implants.
Global Orthopaedic Technologies (Global) supplies implants and instrumentation for hip, knee, shoulder and spine surgeries, along with related orthobiologics. The company was founded in 1999 by Mike Ribot and Steve Banks and has grown to become the largest Australia-owned orthopaedic implant designer and manufacturer. Messrs. Ribot and Banks will continue to be involved with Global as shareholders and senior managers, providing their knowledge and experience of the Australian orthopaedic industry. The company has two research, design and manufacturing facilities in Bella Vista and Seven Hills in New South Wales and is headquartered near Sydney in Baulkham Hills (www.globalortho.com.au).
“Global has an enviable product portfolio and a history of innovation,” said Riverside Partner Simon Feiglin. “They’re a growing company in an expanding market thanks to offering products and services that are valued by surgeons and relied upon by patients in Australia and increasingly around the world.”
Riverside has partnered on the transaction with Andrew Fox-Smith and Duncan Lilley. Mr. Fox-Smith is a former Group President – International with Stryker Corporation, and has more than two decades of experience in the global orthopaedic market. Mr. Fox-Smith will serve as CEO. Mr. Lilley has most recently held senior roles with British Standards Institution and SAI Global and will serve as COO.
“We are delighted to partner with Riverside and Andrew Fox-Smith, who bring their vast international experience to Global, enabling us to develop new and exciting growth opportunities,” Mr. Ribot said. “When Steve and I started Global, it was with a vision to create a multinational orthopaedic business and this transaction is an important milestone in realizing that vision.”
According to Riverside, the firm’s experience in the healthcare sector includes more than 70 investments in the space, supported by a team of specialists who can help Global identify new opportunities and enter new markets.
“By partnering with Riverside, we have an exciting opportunity to not only organically expand Global, but also look at value-added acquisitions that can accelerate our growth objectives,” said Mr. Fox-Smith. “Global offers a comprehensive suite of products, has a demonstrated ability to develop and commercialize new products, and works closely with some of Australia’s leading orthopaedic surgeons. We intend to build on this success and open doors to new relationships and new opportunities to position the company for continued and long-term success.”
Working with Mr. Feiglin on the transaction for Riverside was Vice President Steven Spiteri and Associate Bo Heitz.
The Riverside Company is focused on the smaller end of the middle market and invests in businesses valued at up to $250 million (€200 million in Europe). Since 1988, the firm has invested in more than 340 transactions with a total enterprise value of more than $6 billion. The firm’s international portfolio includes more than 70 companies. The Riverside Company is headquartered in New York with additional offices in Atlanta, Chicago, Cleveland, Dallas, Los Angeles, San Francisco, and London (www.riversidecompany.com).
Babson Capital and Commonwealth Bank of Australia provided financing for the transaction. Jones Day, Deloitte, KPMG and AT Kearney advised Riverside on the deal.
2014 PEPD • Private Equity’s Leading News Magazine • 6-23-14